Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

1. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden 30612115 2019 02 15 1468-2060 78 3 2019 Mar Annals of the rheumatic diseases Ann. Rheum. Dis. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. 320-327 10.1136/annrheumdis-2018-214326 To estimate (1) crude and age-and gender-adjusted (...) incidence rates (IRs) of serious infections (SI) and (2) relative risks (RR) of SI in patients with rheumatoid arthritis (RA) initiating treatment with abatacept, rituximab or tocilizumab in routine care. This is an observational cohort study conducted in parallel in Denmark and Sweden including patients with RA in Denmark (DANBIO) and Sweden (Anti-Rheumatic Treatment in Sweden Register/Swedish Rheumatology Quality Register) who started abatacept/rituximab/tocilizumab in 2010-2015. Patients could

2019 EvidenceUpdates

2. Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate

Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Signal - Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Dissemination Centre Discover Portal NIHR DC Discover Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Published on 24 January 2018 It seems safer to reduce the dose of biological drugs, rather than to stop them if people with rheumatoid arthritis and their doctors want to avoid (...) relapse. Stopping these powerful drugs caused the disease to recur in 58% of people compared with 29% who continued them. Reducing the dose also led to more relapses for people in remission, but did not cause those with low-grade disease activity to worsen. Rheumatoid arthritis is a chronic disease which causes pain, swelling and stiffness in the small joints of the hands and feet. It can cause more widespread inflammation. The disease has episodes of improvement and deterioration so judging

2019 NIHR Dissemination Centre

3. Existing drugs for rheumatoid arthritis may also improve associated fatigue

Existing drugs for rheumatoid arthritis may also improve associated fatigue Signal - Existing drugs for rheumatoid arthritis may also improve associated fatigue Dissemination Centre Discover Portal NIHR DC Discover Existing drugs for rheumatoid arthritis may also improve associated fatigue Published on 23 August 2016 Biological treatments for moderate to severe rheumatoid arthritis appear to reduce fatigue as well as other symptoms. Although existing studies looking at effectiveness have (...) reduction in fatigue, which may be an important consideration for patients and prescribers. Share your views on the research. Why was this study needed? Rheumatoid arthritis affects around 400,000 people in the UK. It is an autoimmune disease in which the person’s own immune system attacks their body, in this case mainly the joints, causing inflammation, swelling, stiffness, pain and irreversible joint damage. There is no cure for rheumatoid arthritis. Treatments such as anti-inflammatory painkillers

2019 NIHR Dissemination Centre

4. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. (PubMed)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. OBJECTIVE: To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors (rituximab, abatacept, and tocilizumab) in the treatment of rheumatoid arthritis. DESIGN: Population based prospective study. SETTING: 53 university and 54 non-university clinical centres in France. PARTICIPANTS: 3162 (...) adults (>18 years) with rheumatoid arthritis according to 1987 American College of Rheumatology criteria, enrolled in one of the three French Society of Rheumatology registries; who had no severe cardiovascular disease, active or severe infections, or severe immunodeficiency, with follow-up of at least 24 months. INTERVENTION: Initiation of intravenous rituximab, abatacept, or tocilizumab for rheumatoid arthritis. MAIN OUTCOME MEASURE: The primary outcome was drug retention without failure at 24

2019 BMJ

5. Effectiveness of a Referral Program for rheumatoid arthritis and axial spondyloarthritis Diagnosis at Primary Care Centers in Portugal - SIARA STUDY. (PubMed)

Effectiveness of a Referral Program for rheumatoid arthritis and axial spondyloarthritis Diagnosis at Primary Care Centers in Portugal - SIARA STUDY. 29506017 2019 01 24 2019 01 24 0303-464X 43 1 2018 Jan-Mar Acta reumatologica portuguesa Acta Reumatol Port Effectiveness of a Referral Program for rheumatoid arthritis and axial spondyloarthritis Diagnosis at Primary Care Centers in Portugal - SIARA STUDY. 40-51 Early diagnosis and treatment of Rheumatoid Arthritis (RA) and axial Spondylarthritis (...) arthritis and axial spondyloarthritis Diagnosis at Primary Care Centers in Portugal – SIARA STUDY. Portugal Acta Reumatol Port 0431702 0303-464X IM Adolescent Adult Aged Arthritis, Rheumatoid diagnosis Female Health Facilities Humans Male Middle Aged Portugal Primary Health Care Prospective Studies Referral and Consultation Spondylarthritis diagnosis Young Adult 2018 3 6 6 0 2019 1 25 6 0 2018 3 6 6 0 ppublish 29506017 AO170231

2019 Acta reumatologica portuguesa

6. Baricitinib (Olumiant) - moderate to severe rheumatoid arthritis (RA)

Baricitinib (Olumiant) - moderate to severe rheumatoid arthritis (RA) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

7. Rheumatoid Arthritis. (PubMed)

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

2019 Annals of Internal Medicine

8. Rheumatoid Arthritis. (PubMed)

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

2019 Annals of Internal Medicine

9. Rheumatoid Arthritis. (PubMed)

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

2019 Annals of Internal Medicine

10. Rheumatoid Arthritis. (PubMed)

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

2019 Annals of Internal Medicine

11. Rheumatoid Arthritis. (PubMed)

Rheumatoid Arthritis. Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer

2019 Annals of Internal Medicine

12. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study 30504445 2019 01 11 1468-2060 78 2 2019 Feb Annals of the rheumatic diseases Ann. Rheum. Dis. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. 179-185 10.1136/annrheumdis-2017-212763 We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced (...) inflammatory arthritis before, and explored biomarkers predictive of arthritis development. Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo. Eighty-one individuals received treatment and were followed up for a mean of 29.0 (0-54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk

2019 EvidenceUpdates

13. Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews

Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Uncertainty remains over the optimal prediction model(s) for early rheumatoid arthritis and there was insufficient evidence that the effect of treatment depended on baseline characteristics. {{author}} {{($index , , , , , , , & . Rachel Archer , * , Emma Hock , Jean Hamilton , John Stevens , Munira Essat , Edith Poku , Mark Clowes , Abdullah Pandor , Matt Stevenson School of Health and Related Research (ScHARR

2018 NIHR HTA programme

14. Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial

Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial 30450972 2018 11 19 1477-0873 2018 Nov 18 Clinical rehabilitation Clin Rehabil Is dry heat treatment (fluidotherapy) effective in improving hand function in patients with rheumatoid arthritis? A randomized controlled trial. 269215518810778 10.1177/0269215518810778 To evaluate the efficacy of dry heat treatment (fluidotherapy) in improving hand function (...) in patients with rheumatoid arthritis. Prospective randomized controlled trial. Departments of Physical Medicine and Rehabilitation and Rheumatology in a university hospital. Patients with rheumatoid arthritis. All patients were randomly divided into two groups. Group 1 underwent dry heat treatment (fluidotherapy) and Group 2 was a control group. Patients in both groups participated in a joint protection and exercise program. Primary outcome measures were Health Assessment Questionnaire and Duruoz Hand

2018 EvidenceUpdates

15. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC/AHA Risk Calculator

Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC/AHA Risk Calculator 30275258 2018 10 02 0315-162X 2018 Oct 01 The Journal of rheumatology J. Rheumatol. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis Is Not Superior to the ACC/AHA Risk Calculator. jrheum.171008 10.3899/jrheum.171008 Cardiovascular (CV) risk estimation calculators for the general population do not perform well (...) in patients with rheumatoid arthritis (RA). An RA-specific risk calculator has been developed, but did not perform better than a risk calculator for the general population when validated in a heterogeneous multinational cohort. In a cohort of patients with new-onset RA from northern Sweden (n = 665), the risk of CV disease was estimated by the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA) and the American College of Cardiology/American Heart Association algorithm (ACC/AHA

2018 EvidenceUpdates

16. Intensive therapy and remissions in rheumatoid arthritis: a systematic review

Intensive therapy and remissions in rheumatoid arthritis: a systematic review 30376836 2018 11 18 1471-2474 19 1 2018 Oct 30 BMC musculoskeletal disorders BMC Musculoskelet Disord Intensive therapy and remissions in rheumatoid arthritis: a systematic review. 389 10.1186/s12891-018-2302-5 We systematically reviewed the effectiveness of intensive treatment strategies in achieving remission in patients with both early and established Rheumatoid Arthritis (RA). A systematic literature review (...) 21360490 N Engl J Med. 2016 Mar 31;374(13):1243-52 27028914 Ann Rheum Dis. 2014 Jun;73(6):1027-36 24618266 Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S56-63 23078808 Clin Exp Rheumatol. 2013 Jul-Aug;31(4):621-32 23622099 Ann Rheum Dis. 2016 Jan;75(1):75-83 26139005 Ann Rheum Dis. 2017 Jan;76(1):96-104 27165179 Arthritis Rheum. 2012 Sep;64(9):2824-35 22508468 Early or established rheumatoid arthritis Outcome Remission Treatment response Lempp Heidi H Sturt Jackie J Prothero Louise L Neatrour Isabel

Full Text available with Trip Pro

2018 EvidenceUpdates

17. Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V

Sarilumab (rheumatoid arthritis) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sarilumab (Rheumatoide Arthritis) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-39 (...) Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-39 Version 1.0 Sarilumab (rheumatoid arthritis) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sarilumab (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study 30194275 2018 09 08 1468-2060 2018 Sep 07 Annals of the rheumatic diseases Ann. Rheum. Dis. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. annrheumdis-2018-213271 10.1136/annrheumdis-2018-213271 This study investigated the effects of dose step-down in patients (...) with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day. Patients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥15 months and maintained CDAI low disease activity (LDA) or remission (REM) were blindly randomised to continue 4 mg or taper to 2 mg. Patients could rescue (to 4 mg) if needed. Efficacy and safety were assessed through 48 weeks. Patients in both groups

2018 EvidenceUpdates

19. Comparing the effect of eye movement desensitization and reprocessing (EMDR) with guided imagery on pain severity in patients with rheumatoid arthritis (PubMed)

Comparing the effect of eye movement desensitization and reprocessing (EMDR) with guided imagery on pain severity in patients with rheumatoid arthritis 30319285 2018 11 14 1178-7090 11 2018 Journal of pain research J Pain Res Comparing the effect of eye movement desensitization and reprocessing (EMDR) with guided imagery on pain severity in patients with rheumatoid arthritis. 2107-2113 10.2147/JPR.S158981 Previous studies reported the reduction of pain following (...) eye movement desensitization and reprocessing (EMDR) and guided imagery; however, the effectiveness of these modalities was not compared. The current study aimed to compare the effects of EMDR and guided imagery on pain severity in patients with rheumatoid arthritis. In this randomized controlled trial, 75 patients were selected using non-random method, and then allocated into two intervention groups and one control group. Interventions were conducted individually in six consecutive sessions for the intervention groups. The Rheumatoid

Full Text available with Trip Pro

2018 EvidenceUpdates

20. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment 30219772 2018 09 16 0315-162X 2018 Sep 15 The Journal of rheumatology J. Rheumatol. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. jrheum.171361 10.3899/jrheum.171361 Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid (...) and poster by all of the authors were presented at the 2017 American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Meeting, November 3-8, San Diego, California, USA: "Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis." J.S. Smolen, MD, Division of Rheumatology, Department of Medicine, Medical University of Vienna; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University

2018 EvidenceUpdates